Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Filanesib, KSP inhibitor · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Filanesib | EXPERIMENTAL | - |
| Carfilzomib + Filanesib | EXPERIMENTAL | Single agent + Carfilzomib arm. Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information. Filgrastim to be administered per the approved product prescribing information and institutional guidelines. |
| Carfilzomib | EXPERIMENTAL | Single agent arm. Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information. |
| Name | Type | Description |
|---|---|---|
| Filanesib, KSP (Eg5) inhibitor; intravenous | DRUG | multiple dose, single schedule |
| Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous | DRUG | standard of care |
| Carfilzomib, proteasome inhibitor; intravenous | DRUG | multiple dose, single schedule |
| Filanesib, KSP(Eg5) inhibitor; intravenous | DRUG | multiple dose, single schedule |
| Dexamethasone, steroid; oral or intravenous | DRUG | as indicated, per the carfilzomib prescribing information |
Key Inclusion Criteria: * Patients with confirmed multiple myeloma whose treatment history must include all of the following: 1. Received at least 2 prior lines of therapy (induction therapy and stem cell transplant ± maintenance are to be considered a single line of therapy). 2. Received at l...
Top 20 of 25 competitors
Filanesib is an investigational small molecule being studied for the treatment of advanced multiple myeloma. It is a kinesin spindle protein (KSP) inhibitor, which means it targets a protein involved in cell division. Filanesib is currently in Phase 2 clinical development and is not yet approved by the FDA.
Filanesib targets kinesin spindle protein (KSP), a protein essential for cell division. By inhibiting KSP, Filanesib is designed to disrupt the division of cancer cells, potentially slowing or stopping tumor growth. This mechanism is being evaluated in clinical trials for advanced multiple myeloma.
Filanesib is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical trials for advanced multiple myeloma, and it remains an investigational agent.
Filanesib is in Phase 2 clinical development. It has completed two Phase 2 trials for advanced multiple myeloma, with a total enrollment of 231 patients. Filanesib is not FDA approved and remains an investigational drug under study.
Filanesib has completed two Phase 2 clinical trials. The first, NCT01989325, studied Filanesib in combination with carfilzomib in 77 patients with advanced multiple myeloma in the United States. The second, NCT02092922, known as the AfFIRM trial, enrolled 154 patients with relapsed or refractory multiple myeloma across multiple countries.
Yes, Filanesib is also known as ARRY-520. In clinical trials, the drug has been referred to by both names. For example, the study NCT01989325 is titled 'A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma,' confirming that Filanesib and ARRY-520 refer to the same investigational drug.